Erythromycin: safety issues | CMAC

Erythromycin: safety issues

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):199-204

​ Matveev A.V., Krasheninnikov A.E., Egorova E.A.
10.36488//cmac.2018.3.199-204
safety erythromycin macrolide antibiotics cardiotoxicity prokinetic properties
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):199-204

Abstract

Macrolide antimicrobials are widely used for the treatment of variety of community-acquired bacterial infections. This paper is aimed to review the data on the safety issues of erythromycin. The main attention is paid to the studies on erythromycin prokinetic properties, cardiotoxicity and fetotoxicity.

Alexander V. Matveev

Medical Academy named after S.I. Georgievsky, Simferopol, Republic of Crimea, Russia
National Pharmacovigilance Research Center, Moscow, Russia

Krasheninnikov A.E.

National Pharmacovigilance Research Center, Moscow, Russia

Egorova E.A.

Medical Academy named after S.I. Georgievsky, Simferopol, Republic of Crimea, Russia

  • 1. Posohova К.А., Viktorov A.V. Antibiotics. Tepnopol: TGMY, «Ukrmedkniga», 2005. 296 p. Russian.
  • 2. Yakovleva V.P., Yakovleva S.V. Rational antimicrobial pharmacotherapy: a guide for practicing physicians. M.: Litterra, 2003. 1008 p. Russian.
  • 3. Strachunskij L.S., Belousovа Yu.B., Kozlov S.N. Practical guidance on anti-infectious chemotherapy. Smolensk: MAKMAX, 2002. 350 p. Russian.
  • 4. Shilenkova V.V. Five reasons to prescribe macrolides in diseases of ENT organs. Medicinskij sovet. 2016;9:40-44. Russian.
  • 5. Amirov N.B., Vizel A.A. Macrolides in the treatment of various bacterial infections. Vestnik sovremennoj klinicheskoj mediciny. 2012;5(4):43. Russian.
  • 6. Mandell G.L., Douglas R.G., Bennett J.E., et al. Anti-infective therapy. New York; Edinburgh, London, Melbourne 1985. p. 197-218.
  • 7. Zaplatnikov A.P. Macrolide antibiotics in the treatment of respiratory infections in children. Lechebnoe delo. 2002;1:32-37. Russian.
  • 8. Rachina S.A., Stratchounski L.S., Kozlov S.N. Clarithromycin: Is there potential for clinical use in the 21st century? Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2005;7(4):369-392. Russian.
  • 9. Greenwood D. Antimicrobial Chemotherapy. Oxford; New York: Oxford University Press; 1995. 485 p.
  • 10. Poluzzi E., Raschi E., Motoka D., Moretti U., De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-14.
  • 11. Simko J., Gsilek A., Karaszi J., et al. Proarrhythmic potential of antimicrobial agents. Infection. 2008;36(3):194-206.
  • 12. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219233.
  • 13. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363-1372.
  • 14. Schoenenberger R.A., Haefeli W.E., Weiss P., Ritz R.F. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes). BMJ. 1990;300:13751376.
  • 15. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
  • 16. Guo D., Cai Y., Chai D., Liang B., et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631-640.
  • 17. Cheng Y.J., Nie X.Y., Chen X.M., et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol. 2015;66(20):2173-2184.
  • 18. Williams J.D. Evaluation of the safety of macrolides. Int J Antimicrob Agents. 2001;18(Suppl 1): S77-S81.
  • 19. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(Suppl 1):S71-S76.
  • 20. Tropskaja N.S., Popova T.S., Soloveva G.I. The mechanism of prokinetic action of erythromycin. Proceedings of IX International Congress "Parenteral and enteral nutrition". Moscow, December 1516, 2005. p. 92. Russian.
  • 21. Takeshita E., Matsuura B., Dong M.J., et al. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. Gastroenterology. 2006;41(3):223-230.
  • 22. Waseem S., Moshiree B., Draganov P.V. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol. 2009;15(1):25-37.
  • 23. Richards R.D., Davenport K., McCallum R.W. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88(2):203-207.
  • 24. Ehrenpreis E.D., Zaitman D., Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmacokinetic analysis. Aliment Pharmacol Ther. 1998;12(4):373-376.
  • 25. Kawamura O., Sekiguchi T., Kusano M., Nishioka T., Itoh Z. Effect of erythromycin on interdigestive gastrointestinal contractile activity and plasma motilin concentration in humans. Dig Dis Sci. 1993;38(5):870876.
  • 26. Dalgic B., Sari S., Dogan I., Ünal S. Chronic intestinal pseudoobstruction: Report of four pediatric patients. Turk J Gastroenterol. 2005;16:93-97.
  • 27. Alekseeva E.V., Popova T.S., Tropskaya N.S. Some aspects of the use of prokinetic properties of erythromycin. Kremlevskaja medicina. Klinicheskij vestnik. 2009;4:80-86. Russian.
  • 28. Semenihina T.M., Ryzhih R.G., Onopriev V.V., Mezenceva K.Yu. Experience in the use in the surgical hospital of erythromycin for the correction of motor disorders of the stomach and duodenum. Kubanskij nauchnyj medicinskij vestnik. 2007;(4-5):120-123. Russian.
  • 29. Ericson J.E., Arnold C., Cheeseman J. Use and safety of Erythromycin and Metoclopramide in hospitalized infants. J Pediatr Gastroenterol Nutr. 2015;61(3):334-339.
  • 30. Ng Y.Y., Su P.H., Chen J. Y., Quek Y.W. Efficacy of intermediatedose oral erythromycin on very low birth weight infants with feeding intolerance. Pediatr Neonatol. 2012;53(1):34-40.
  • 31. Tonelli A.R., Drane W.E., Collins D.P., et al. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros. 2009;8(3):193-197.
  • 32. Källén B.A., Otterblad Olausson P., Danielsson B.R. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20(2):209214.
  • 33. Lin K.J., Mitchell A.A., Yau W.P. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208(3):221.e1-8.
  • 34. Bérard A., Sheehy O., Zhao J.P., Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24(12):1241-1248.
  • 35. Bahat Dinur A., Koren G., Matok I., et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57(7):3307-3311.
  • 36. Goldstein L.H., Berlin M., Tsur L., et al. The safety of macrolides during lactation. Breastfeed Med. 2009;4(4):197-200.
  • 37. Review on Antimicrobial Resistance. Wellcome Trust and the UK Department of Health. Available at: https://amr-review.org/. Accessed 21.12.2017.
  • 38. Kosarev V.V., Babanov S.A. Clinical pharmacology of macrolides. Antimikrobnaja terapija i pul'monologija. 2012;408:61-65. Russian.
  • 39. Sinopalnikov A.I., Guchev I.A. Macrolides: a modern concept of application. Russkij medicinskij zhurnal. 2003;2:88. Russian.
  • 40. Mechanisms of resistance to antibacterial drugs of different groups. Available at: www.antibiotic.ru/index.php?doc=98. Accessed 19.12.2017. Russian.
  • 41. Hashimoto H., Toide K., Kitamura R., Fujita M., et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem. 1993;218(2):585-595.
  • 42. Simvastatin: new contraindications, precautions and dosage recommendations. Available at: www.tga.gov.au/alert/simvastatinnew-contraindications-precautions-and-dosage-recommendations. Accessed 10.01.2018.
  • 43. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Available at: www.fda.gov/drugs/ drugsafety/ucm293101.htm. Accessed 10.01.2018.
  • 44. Simvastatin: updated advice on drug interactions. Available at: www.gov.uk/drug-safety-update/simvastatin-updated-advice-on-druginteractions. Accessed 10.01.2018.
  • 45. New data on the possible interaction of erythromycin with ergotamine and colchicine. Available at: www.dari.kz/pages/964. Accessed 15.01.2018.
  • 46. Escitalopram (Seroplex®) et allongement dose-dépendant de l’intervalle QT. Available at: http://ansm.sante.fr/var/ansm_site/ storage/original/application/8507c2b9d18019576f0d2e13a53c 2cbf.pdf. Accessed 01.12.2018.
  • 47. Domperidone – QT-interval prolongation and associated arrhythmia. Available at: www.swissmedic.ch/marktueberwachung/. Accessed 01.12.2018.
  • 48. Quetiapinum. Safety precautions. Available at: www.dec.gov.ua/index.php/ua/zvedena-informatsiya-z-bezpeki/zasterezhennya-z-bezpeki2014/327-17-06-14-zasterezhennya-z-bezpeki/352-kvetiapin. Accessed 01.12.2018. Ukranian.
  • 49. Domperidon. Safety precautions. Available at: www.dec.gov.ua/index.php/ua/zvedena-informatsiya-z-bezpeki/zasterezhennyaz-bezpeki-2013⁄146-25-04-13-zasterezhennya-z-bezpeki/157domperidon. Accessed 01.12.2018. Ukranian.
  • 50. Amendments have been made to the instructions for the medical use of drugs with INN – domperidone in the dosage form of a tablet, suspension, drops, syrup. Available at: http://dari.kz/pages/1404. Accessed 01.12.2018. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared